BRM.DE
Get informed when a big investor buys or sells
+ FollowUndervalued by 168.5% based on the discounted cash flow analysis.
| Market cap | $103.45 Billion |
|---|---|
| Enterprise Value | $137.85 Billion |
| Dividend Yield | $2.21 (4.26%) |
| Earnings per Share | $3.47 |
| Beta | 0.24 |
| Outstanding Shares | 2,042,000,000 |
| P/E Ratio | 13.02 |
|---|---|
| PEG | 8.5 |
| Price to Sales | 2.11 |
| Price to Book Ratio | 5.07 |
| Enterprise Value to Revenue | 2.8 |
| Enterprise Value to EBIT | 11.26 |
| Enterprise Value to Net Income | 14 |
| Total Debt to Enterprise | 0.31 |
| Debt to Equity | 1.93 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
No data
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.